# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 51-60 of 2712 results.
The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients
Status: Recruiting
Last Changed: Jan 16, 2017
First Received: Jan 12, 2017
Disease(s): Ovarian Cancer
Locations: National Taiwan University, Taipei, Taiwan
Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
Status: Active, not recruiting
Last Changed: Jun 26, 2019
First Received: Aug 16, 2016
Disease(s): Ovarian Cancer
Intervention(s): Apatinib, Etoposide
Locations: Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.
Status: Completed
Last Changed: Nov 20, 2019
First Received: Sep 24, 2018
Disease(s): Ovarian Cancer Recurrent
Intervention(s): Doxorubicin Hydrochloride Liposome Injection
Locations: MNJ Institute of Oncology & Regional Cancer Center, Hyderabad, Andhra Pradesh, India
HCG City Cancer Centre, Vijayawada, Andhra Pradesh, India
Mahatma Gandhi Cancer Hospital & Research Institute, Visakhapatnam, Andhra Pradesh, India
Nirmal Hospital Pvt. Ltd., Surat, Gujarat, India
Unique Hospital - Multispeciality and Research Institute, Sūrat, Gujarat, India
... and 11 other locations.
Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer
Status: Completed
Last Changed: Feb 10, 2016
First Received: Nov 11, 2010
Disease(s): Epithelial Ovarian Cancer
Intervention(s): Pazopanib
Locations: Marienkrankenhaus Hamburg, Hamburg, Germany
Universitäts-Frauenklinik, Heidelberg, Germany
Klinikum Konstanz Gynäkologie und Geburtshilfe, Konstanz, Germany
Universitätsmedizin der Johannes Gutenberg-Universität Mainz Klinik und Poliklinik für Geburtshilfe und Frauenheilkunde, Mainz, Germany
Universitätsfrauenklinik Tübingen Klinik für Gynäkologie und Geburtshilfe, Tübingen, Germany
... and 1 other locations.
Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer
Status: Completed
Last Changed: Oct 15, 2014
First Received: Mar 12, 2013
Disease(s): Recurrent Ovarian Cancer
Intervention(s): chemotherapy with doxorubicin and cisplatin
Locations: Ruhr University Bochum, Bochum, NRW, Germany
Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer
Status: Terminated
Last Changed: Dec 15, 2009
First Received: Apr 24, 2006
Disease(s): Ovarian Cancer
Intervention(s): lapatinib
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Indiana University School of Medicine, Indianapolis, Indiana, United States
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
Status: Completed
Last Changed: Dec 22, 2014
First Received: Oct 20, 2006
Disease(s): Ovarian Cancer
Intervention(s): Sorafenib, Paclitaxel, Carboplatin
Locations: Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
Florida Cancer Specialists, Fort Myers, Florida, United States
Holy Cross Hospital, Ft. Lauderdale, Florida, United States
Gulfcoast Oncology Associates, St. Petersburg, Florida, United States
Medical College of Georgia Cancer Specialists, Augusta, Georgia, United States
... and 13 other locations.
Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer
Status: Completed
Last Changed: Jul 24, 2018
First Received: Mar 23, 2009
Disease(s): Ovarian Cancer
Intervention(s): Bendamustine HCL
Locations: Arizona Cancer Center, Tucson, Arizona, United States
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
Status: Terminated
Last Changed: Jan 14, 2020
First Received: May 10, 2017
Disease(s): Ovarian Cancer
Intervention(s): NUC-1031 500 mg, NUC-1031 750mg
Locations: Arizona Oncology Associates, PC - HAL, Scottsdale, Arizona, United States
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
University of California, Orange, California, United States
Rocky Mountain Cancer Centers, LLP, Lakewood, Colorado, United States
Florida Cancer Affiliates - Ocala, Ocala, Florida, United States
... and 18 other locations.
Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer
Status: Recruiting
Last Changed: Nov 13, 2017
First Received: Nov 07, 2017
Disease(s): Ovarian Cancer
Intervention(s): Fludarabine and Pegylated liposomal doxorubicin, Pegylated liposomal doxorubicin
Locations: Sun Yat-sen University Cancer, Guangzhou, Guangdong, China